Background Hormone therapy (HT) is widely used for controlling menopausal symptoms
and has also been used for the management and prevention of cardiovascular disease …

Objective To assess the risk of venous thromboembolism in women using hormone
replacement therapy by study design, characteristics of the therapy and venous …

Background Oral oestrogen-replacement therapy (ERT) activates blood coagulation and
increases the risk of venous thromboembolism (VTE) in postmenopausal women …

Estrogen-containing medication, prescribed either for contraception in women of
reproductive age or for prevention of cardiovascular events and osteoporosis as well as for …

Context Testing for genetic risks for venous thromboembolism (VTE) is common, but the
safety and utility of such testing need review. Objectives To define rates of recurrent VTE …

The use of oral contraceptives (OC) is a well established risk factor for venous thrombosis. It
has been known for many years that almost all haemostatic parameters ie plasma levels of …

Recent publications describing the results of the Women's Health Initiative (WHI) and other
studies reporting the impact of hormone therapy on aging women have spurred …

Obesity has emerged as a global health issue that is associated with wide spectrum of
disorders, including coronary artery disease, diabetes mellitus, hypertension, stroke, and …

There is now strong experimental evidence that tissue factor pathway inhibitor (TFPI) is a
critical inhibitor to modulate tissue factor–induced coagulation, but the role of TFPI as a risk …

The generation of thrombin by the prothrombinase complex constitutes an essential step in
hemostasis, with thrombin being crucial for the amplification of blood coagulation, fibrin …